SERPINE1 and obesity disorder: In a population-based nested case-control study from Tromsø, Norway, the future risk of VTE increased in a dose-dependent manner with increasing PAI-1 at baseline, and PAI-1 explained approximately 15% of the VTE risk in obesity [64].